Over the weekend, Clovis Oncology took another big step toward its near-term goal of launching commercial operations, with plans to take pharma giant AstraZeneca head-on with two key franchise showdowns. The Boulder, CO-based biotech posted positive data from a mid-stage study of its ovarian cancer drug rucaparib at ASCO, while adding new–though less impressive–data to […]
Celldex has added another round of positive data demonstrating that its brain cancer vaccine rindopepimut–more formally called Rintega and less formally “rindo”–provided a clear though relatively modest average survival benefit for recurrent glioblastoma patients in a Phase II study. And with the initial data set from Phase III looming later in the year, the biotech […]
Behind the headlines here at ASCO, you’ll find one of the biggest players in immuno-oncology quietly positioning itself to grab a leading role in the fast-emerging market. …read more Source: Genentech’s PD-L1 breakthrough star ‘atezo’ positioned to vault ahead on cancer
CTI BioPharma and its partner Baxter outlined positive Phase III data for their myelofibrosis drug pacritinib, which may help pave a way to position the therapy against Jakafi next year. …read more Source: ASCO: CTI’s myelofibrosis drug pacritinib posts competitive PhIII data
It was Johnson & Johnson’s turn to take center stage at ASCO Saturday morning, fleshing out the promising data that it accumulated in a Phase II study of daratumumab for treatment-resistant multiple myeloma. …read more Source: J&J builds promising case for multiple myeloma competitor daratumumab
Bristol-Myers Squibb and rival Merck started off the big annual scientific meeting of ASCO with a bang, rolling out a slate of new studies spotlighting the growing body of evidence that their new immuno-oncology drugs will play a key role fighting a range of cancers. …read more Source: UPDATED: Bristol-Myers dominates–and disappoints–at ASCO immuno-oncology debut […]
Some analysts may be pooh-poohing a Pfizer buyout of GlaxoSmithKline, but some investors are hip to the idea. …read more Source: Investors warm up to the idea of Pfizer snapping up GSK
AstraZeneca believes the brightest future for its top oncology prospect will come through collaboration, recruiting Eli Lilly to its growing ranks of partners with eyes on kicking off a combination cancer trial. …read more Source: AstraZeneca adds Lilly to its stable of immuno-oncology collaborators
After posting a trio of Phase III victories, Amgen is plotting to submit the kidney dialysis drug AMG 416 for FDA review this year, charging forward with a successor to its own Sensipar. …read more Source: Amgen preps an FDA pitch for its late-stage kidney drug
Heron Therapeutics is gearing up for a third attempt at FDA approval for its chemotherapy-induced nausea and vomiting drug, posting a Phase III success after repeated delays. …read more Source: Heron soars as twice-rejected nausea drug comes through in Phase III
